Advancing Against Drug-resistant Tuberculosis: an Extensive Review, Novel Strategies and Patent Landscape

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Oct 8

PMID 39377922

Authors

Meghana N Patel

Archita J Patel

Manish N Nandpal

Manan A Raval

Ravish J Patel

Amit A Patel

Keshav Raj Paudel

Philip M Hansbro

Sachin Kumar Singh

Gaurav Gupta

Kamal Dua

Samir G Patel

Affiliations

Soon will be listed here.

Abstract

Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions.

References

Aggarwal A, Mehta S, Gupta D, Sheikh S, Pallagatti S, Singh R . Dental students' motivations and perceptions of dental professional career in India. J Dent Educ. 2012; 76(11):1532-9. View

Ahmed S, Nandi S, Saxena A . An updated patent review on drugs for the treatment of tuberculosis (2018-present). Expert Opin Ther Pat. 2021; 32(3):243-260. DOI: 10.1080/13543776.2022.2012151. View

Alemu A, Bitew Z, Diriba G, Gashu E, Seid G, Eshetu K . Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis. BMJ Open. 2023; 13(4):e070143. PMC: 10083796. DOI: 10.1136/bmjopen-2022-070143. View

Washburn J, Varela J, Xavier A, Chen Q, Ertl D, Gage J . Global Genotype by Environment Prediction Competition Reveals That Diverse Modeling Strategies Can Deliver Satisfactory Maize Yield Estimates. bioRxiv. 2024; . PMC: 11429743. DOI: 10.1101/2024.09.13.612969. View

Alzahabi K, Usmani O, Georgiou T, Ryan M, Robertson B, Tetley T . Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies. Emerg Top Life Sci. 2020; 4(6):581-600. PMC: 7752053. DOI: 10.1042/ETLS20190154. View

Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher L . Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother. 2005; 50(1):104-12. PMC: 1346799. DOI: 10.1128/AAC.50.1.104-112.2006. View

Aung K, Van Deun A, Declercq E, Sarker M, Das P, Hossain M . Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-7. DOI: 10.5588/ijtld.14.0100. View

Bakhtiyariniya P, Khosravi A, Hashemzadeh M, Savari M . Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran. Mol Biol Rep. 2022; 49(7):6135-6143. PMC: 8976162. DOI: 10.1007/s11033-022-07404-2. View

Beviere M, Reissier S, Penven M, Dejoies L, Guerin F, Cattoir V . The Role of Next-Generation Sequencing (NGS) in the Management of Tuberculosis: Practical Review for Implementation in Routine. Pathogens. 2023; 12(8). PMC: 10459500. DOI: 10.3390/pathogens12080978. View

10.

Borah Slater K, Kim D, Chand P, Xu Y, Shaikh H, Undale V . A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy. Trop Med Infect Dis. 2023; 8(2). PMC: 9965948. DOI: 10.3390/tropicalmed8020100. View

11.

Calligaro G, Moodley L, Symons G, Dheda K . The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis. 2014; 6(3):186-95. PMC: 3949182. DOI: 10.3978/j.issn.2072-1439.2013.11.11. View

12.

Campbell P, Morlock G, Sikes R, Dalton T, Metchock B, Starks A . Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011; 55(5):2032-41. PMC: 3088277. DOI: 10.1128/AAC.01550-10. View

13.

Chiang C, Centis R, Migliori G . Drug-resistant tuberculosis: past, present, future. Respirology. 2010; 15(3):413-32. DOI: 10.1111/j.1440-1843.2010.01738.x. View

14.

Chopra H, Mohanta Y, Ranjan Rauta P, Ahmed R, Mahanta S, Mishra P . An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management. Pharmaceuticals (Basel). 2023; 16(4). PMC: 10145450. DOI: 10.3390/ph16040581. View

15.

Cuevas-Cordoba B, Cuellar-Sanchez A, Pasissi-Crivelli A, Santana-Alvarez C, Hernandez-Illezcas J, Zenteno-Cuevas R . rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. J Microbiol Immunol Infect. 2012; 46(1):30-4. DOI: 10.1016/j.jmii.2012.08.020. View

16.

Dartois V, Rubin E . Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022; 20(11):685-701. PMC: 9045034. DOI: 10.1038/s41579-022-00731-y. View

17.

Alves da Silva D, Ferreira N, Rego A, Barbosa P, Machado R, Pimentel A . Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates. Tuberculosis (Edinb). 2018; 113:163-174. DOI: 10.1016/j.tube.2018.08.010. View

18.

Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A . High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol. 2011; 50(4):1390-6. PMC: 3318526. DOI: 10.1128/JCM.05286-11. View

19.

Dheda K, Gumbo T, Gandhi N, Murray M, Theron G, Udwadia Z . Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014; 2(4):321-38. PMC: 5526327. DOI: 10.1016/S2213-2600(14)70031-1. View

20.

Dohal M, Porvaznik I, Solovic I, Mokry J . Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine. Front Microbiol. 2023; 14:1225438. PMC: 10582268. DOI: 10.3389/fmicb.2023.1225438. View